HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Raises Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns maintains a Buy rating on Nurix Therapeutics and raises the price target from $26 to $30.
October 21, 2024 | 11:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reaffirmed its Buy rating on Nurix Therapeutics and increased the price target from $26 to $30, indicating a positive outlook.
The reaffirmation of a Buy rating and an increased price target from a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100